News | July 16, 2022
Indian pharmaceutical companies to grow by 6-7% in FY2023: ICRA
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
Ranked 25th with an impressive growth rate of 29% among Indian pharma companies in FY 2021-22
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Fiscal support in line with what is available in key innovation hubs such as USA and China will drive the next leg of drug discovery in India
The stability is led by healthy demand in the domestic and emerging markets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company will market it under the brand name Molflu
Subscribe To Our Newsletter & Stay Updated
